Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy.

Junji Furuse Masafumi Ikeda Makoto Ueno Masayuki Furukawa Chigusa Morizane Tetsuo Takehara Tomohiro Nishina Akiko Todaka Naohiro Okano Kazuo Hara Yousuke Nakai Kazuyoshi Ohkawa Takashi Sasaki Kazuya Sugimori Naoyuki Yokoyama Kouji Yamamoto

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Compared with placebo, nanvuranlat improved PFS in patients with advanced and refractory BTC with an acceptable safety profile. Further studies of this promising compound are warranted in the population of patients who are exhausted from treatment options.

Keyphrases

phase ii
clinical trial
double blind
newly diagnosed
end stage renal disease
ejection fraction
open label
prognostic factors
placebo controlled
randomized controlled trial
squamous cell carcinoma
radiation therapy
study protocol
drug induced